Repository of Research and Investigative Information

Repository of Research and Investigative Information

Larestan University of Medical Sciences

Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

(2019) Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal of Cellular Physiology. pp. 5628-5642. ISSN 0021-9541

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody-drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy. The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower levels of unconjugated mAbs and more-stable linkers between the drug and the antibody, which show improved pharmacokinetic properties, therapeutic indexes, and safety profiles. Such improvements resulted in the US Food and Drug Administration approvals of brentuximab vedotin, trastuzumab emtansine, and, more recently, inotuzumab ozogamicin. In addition, recent clinical outcomes have sparked additional interest, which leads to the dramatically increased number of ADCs in clinical development. The present review explores ADCs, their main characteristics, and new research developments, as well as discusses strategies for the selection of the most appropriate target antigens, mAbs, cytotoxic drugs, linkers, and conjugation chemistries.

Item Type: Article
Keywords: antibody-drug conjugate conjugation cytotoxic small molecules linkers monoclonal antibody monoclonal-antibody antitumor-activity intracellular trafficking dependent internalization targeted chemotherapy gemtuzumab ozogamicin brentuximab vedotin next-generation cytotoxic drug human igg2 Cell Biology Physiology
Divisions: Education Vice-Chancellor Department > Faculty of Nursing and Midwifery > Department of Nursing
Page Range: pp. 5628-5642
Journal or Publication Title: Journal of Cellular Physiology
Journal Index: ISI
Volume: 234
Number: 5
Identification Number: https://doi.org/10.1002/jcp.27419
ISSN: 0021-9541
Depositing User: مهندس مهدی شریفی
URI: http://eprints.larums.ac.ir/id/eprint/378

Actions (login required)

View Item View Item